Moll María Elena Camacho, Martínez Ana María Salinas, Cisneros Benjamín Tovar, Onofre Juan Ignacio García, Floriano Gloria Navarrete, de León Mario Bermúdez
Department of Molecular Biology, Northeast Biomedical Research Center, Mexican Institute of Social Security, Monterrey 64720, N.L., Mexico.
Center for Molecular Diagnosis and Personalized Medicine, Health Sciences Division, Universidad de Monterrey, San Pedro Garza García 66238, N.L., Mexico.
Vaccines (Basel). 2023 Jul 25;11(8):1280. doi: 10.3390/vaccines11081280.
COVID-19 vaccines' safety has been extensively studied; however, further analysis is required in pregnant women, nursing mothers, and breastfed infants. Our aim was to compare the extension and severity of self-reported COVID-19 vaccine side effects in pregnant and breastfeeding women, and breastfed infants. In this cross-sectional study, COVID-19-vaccinated subjects were enrolled using an online survey in Mexico. Women were classified by pregnancy and breastfeeding status at the time of vaccination ( = 3167). After the first or only dose, there was a trend toward fewer systemic effects in pregnant women ( = 0.06). BNT162b2 (Pfizer-BioNTech) had a higher frequency of local symptoms in pregnancy. Lactating women experienced fewer local symptoms after the first or single dose ( = 0.04) and the opposite occurred after the second dose ( = 0.001). ChAdOx1 (AstraZeneca) increased the chances of developing both local and systemic symptoms after the first dose but decreased them after the second dose. The severity was similar across groups, although the result of lack of association in pregnancy requires studies with a larger sample size. Irritability was the most reported symptom in breastfed infants. This study contributes to the knowledge about the side effects in pregnant and lactating women, and breastfed babies.
新冠疫苗的安全性已得到广泛研究；然而，仍需要对孕妇、哺乳期母亲和母乳喂养婴儿进行进一步分析。我们的目的是比较孕妇、哺乳期妇女和母乳喂养婴儿自我报告的新冠疫苗副作用的范围和严重程度。在这项横断面研究中，通过在线调查在墨西哥招募了接种新冠疫苗的受试者。根据接种疫苗时的怀孕和母乳喂养状况对女性进行分类（n = 3167）。在接种第一剂或唯一一剂疫苗后，孕妇出现全身反应的趋势较少（P = 0.06）。BNT162b2（辉瑞 - 生物科技公司）在孕期出现局部症状的频率较高。哺乳期妇女在接种第一剂或单剂疫苗后出现局部症状较少（P = 0.04），而在接种第二剂后情况相反（P = 0.001）。ChAdOx1（阿斯利康）在接种第一剂后出现局部和全身症状的几率增加，但在接种第二剂后降低。尽管孕期缺乏关联的结果需要更大样本量的研究，但各群体的严重程度相似。烦躁是母乳喂养婴儿中报告最多的症状。这项研究有助于了解孕妇、哺乳期妇女和母乳喂养婴儿的副作用情况。
